Picture of Divi's Laboratories logo

DIVISLAB — Divi's Laboratories News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Preview: India's Sun Pharma rises ahead of Q3 results

** Shares of Sun Pharma  SUN.NS , India's top drugmaker by
revenue, rise 3.6% to 1,420.85 rupees
    ** Stock second-biggest gainer on 20-member Nifty pharma
index  .NIPHARM 
    ** Analysts expect SUN's Q3 profit and rev to rise 12% and
9.5%, per LSEG, vs 5% rise in Q2 profit and ~11% Q2 rev growth
    ** SUN to see steady growth in FY23-26, led by uptick in
specialty products and domestic business - HSIE
    ** Likely launch of hair loss treatment drug Deuruxolitinib
in H2FY25 to add to specialty business' growth - Elara Capital
    ** Registration of Ilumya, drug for treating plaque
psoriasis, in China, will drive growth - Elara 
    ** Analysts rate SUN, Cipla  CIPL.NS  at "buy", Dr Reddy's
 REDY.NS  rated "hold"- LSEG data
    ** CIPL, REDY beat quarterly profit estimates on strong U.S.
sales
    ** SUN's 26% rise in 2023 higher than CIPL's 16%, but short
of REDY's 37% climb
    

 (Reporting by Kashish Tandon in Bengaluru)
 ((kashish.tandon@thomsonreuters.com))

Recent news on Divi's Laboratories

See all news